Amended Current Report Filing (8-k/a)
October 16 2018 - 11:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
October 16, 2018
(October 12, 2018)
Heyu
Biological Technology Corporation
(Exact Name of Registrant as Specified in its
Charter)
Nevada
|
|
000-26731
|
|
87-0627910
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification Number)
|
4th Floor, No. 10 Building, Xinglin Bay Business
Operation Center,
Jimei District, Xiamen City,
Fujian Province, China 361022
(Address of Principal Executive Offices, Zip
Code)
Registrant’s telephone number, including
area code:
(86) 158 5924 0902
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
We are filing this amendment to include
updated information of the disclosure contained in the initial 8-K filing, made on October 12, 2018 (the “Initial 8-K”);
additional information on Ms. Kwee Huwa Tan’s resume were inadvertently omitted from the Initial 8-K.
No other changes have been made to the Initial 8-K. This Amendment
speaks as of the original filing date, does not reflect events that may have occurred subsequent to the original filing date,
and does not modify or update in any way disclosures made in the Initial 8-K.
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
|
Appointment of New Director – Kwee
Huwa Tan
On October 12, 2018, Ms. Kwee Huwa Tan was
appointed to the Board of Directors of the Company to serve as a director of the Company.
There is no understanding or arrangement
between Ms. Tan and any other person pursuant to which she was appointed as director. Ms. Tan does not have any family relationship
with any director, executive officer or person nominated or chosen by the Company’s board to become a director or an executive
officer. Ms. Tan has not had direct or indirect material interest in any transaction or proposed transaction, in which the Company
was or is a proposed participant, exceeding $120,000.
Ms. Kwee Huwa Tan, age 54, is a sales
& marketing expert with a strong entrepreneurial spirit. She is the founder and Chief Executive Officer of Isbel Beauty Centre.,
a provider of primer skin care products, and a company founded in 2012. Ms. Tan has also served as the Chief Advisor to Heyu Biological
Technology Corporation (Xiamen) since 2013 where she was tasked with developing networking opportunities, analyzing profitability
of products and market potentials and cultivating prospective clients. Ms. Tan has also served as a director of Heyu Leisure Holidays
Corporation, and on its Nominating and Compensation Committee since 2017. Ms. Tan obtained her bachelor degree in Business Administration
from Ansted University in Malaysia in the year of 2014.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Heyu Biological
Technology Corporation
|
|
|
|
By:
|
/s/
Ban Siong Ang
|
|
Name:
Title:
|
Ban Siong Ang
Chief Executive
Officer
|
|
|
|
|
Date:
|
October 16, 2018
|
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Apr 2023 to Apr 2024